瑞波西利联合来曲唑治疗复发性低级别浆液性卵巢癌的II期试验
这项开放标签、单臂、多中心II期研究评估了瑞波西利联合来曲唑在复发性低级别浆液性卵巢癌(LGSOC)患者中的疗效和安全性。共49例患者接受治疗,确认的客观缓解率(ORR)为30.6%,临床获益率(CBR)为84%,中位无进展生存期(PFS)为14.5个月,中位总生存期(OS)为44.5个月。常见≥3级不良事件为中性粒细胞减少(47%),安全性特征与既往CDK4/6抑制剂研究一致。该联合方案达到了主要终点,在此罕见亚型中显示出有意义的缓解率和持久的疾病控制。
要点
- 瑞波西利联合来曲唑在复发性LGSOC中确认ORR达30.6%,中位缓解持续时间21.2个月。
- 中位PFS为14.5个月,中位OS为44.5个月,CBR为84%。
- 常见≥3级不良事件为中性粒细胞减少(47%),可通过剂量调整管理。
核心结论
- 瑞波西利联合来曲唑达到了主要终点,在复发性LGSOC中显示出有意义的缓解率和持久的疾病控制。
研究设计与样本
- 开放标签、单臂、多中心II期研究,纳入可测量复发性LGSOC女性患者,共51例入组、49例接受治疗。
- 患者接受瑞波西利600 mg口服每日一次(28天周期中第1-21天)联合来曲唑2.5 mg口服每日一次。
- 主要终点为研究者根据RECIST 1.1评估的客观缓解率(ORR),次要终点包括临床获益率(CBR)、无进展生存期(PFS)、总生存期(OS)和安全性。
主要发现
- 确认的ORR为30.6%(90% CI, 19.9-43.2),包括1例完全缓解和14例部分缓解。
- 缓解者的中位缓解持续时间为21.2个月。
- CBR为84%(90% CI, 72.5-91.6)。
- 中位PFS为14.5个月(90% CI, 10.1-28.8),中位OS为44.5个月(90% CI, 31.8-未达到)。
- 最常见的≥3级不良事件为中性粒细胞减少(47%),通过剂量调整管理;3例(6%)5级事件与治疗无关;4%因不良事件终止治疗;未观察到剂量限制性毒性。
关键数值与推荐
- 确认ORR 30.6%(90% CI, 19.9-43.2),CBR 84%(90% CI, 72.5-91.6)。
- 中位PFS 14.5个月(90% CI, 10.1-28.8),中位OS 44.5个月(90% CI, 31.8-未达到)。
- ≥3级中性粒细胞减少发生率47%,5级事件6%(与治疗无关),因不良事件终止治疗4%。
临床怎么用
- 对于复发性低级别浆液性卵巢癌,瑞波西利联合来曲唑可作为治疗选择,尤其适用于ER表达和CDK4/6通路失调的患者。
- 治疗期间需监测中性粒细胞减少,必要时进行剂量调整。
局限性
- 单臂设计,无对照,样本量较小(49例接受治疗),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)-p16-Rb pathway, features shared with hormone receptor-positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS: This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION: Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
引用
- Slomovitz BM, Weroha SJ, Deng W, et al. Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). J Clin Oncol. 2025. PMID: 41385758. doi:10.1200/JCO-25-01348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。